Currently out of the existing stock ratings of Jonathan Chang, 93 are a BUY (63.7%), 53 are a HOLD (36.3%).

Jonathan Chang

Work Performance Price Targets & Ratings Chart

Analyst Jonathan Chang, carries an average stock price target met ratio of 53.04% that have a potential upside of 40.76% achieved within 238 days.

Jonathan Chang’s has documented 271 price targets and ratings displayed on 22 stocks. The coverage was on Healthcare, Consumer Cyclical sectors.

Most recent stock forecast was given on REPL, Replimune Group at 04-Aug-2026.

Wall Street Analyst Jonathan Chang

Analyst best performing recommendations are on REPL (REPLIMUNE GROUP).
The best stock recommendation documented was for REPL (REPLIMUNE GROUP) at 4/13/2026. The price target of $2 was fulfilled within 1 day with a profit of $2.76 (57.98%) receiving and performance score of 579.83.

Average potential price target upside

of $71.23 (33.55%) on KPTI (KARYOPHARM THERAPEUTICS).
of $27.39 (64.44%) on VINC (VINCERX PHARMA).
of $18.67 (34.95%) on RVMD (REVOLUTION MEDICINES).

ADAP Adaptimmune Therapeutics Plc CALA Calithera Biosciences IMGN ImmunoGen IMTX Immatics NV KPTI Karyopharm Therapeutics MGNX MacroGenics ZLAB Zai Lab Ltd BCYC Bicycle Therapeutics Ltd GMAB Genmab AS HARP Harpoon Therapeutics KURA Kura Oncology REPL Replimune Group RVMD Revolution Medicines ATNX Athenex RUBY Rubius Therapeutics TCRR Tcr2 Therapeutics VINC Vincerx Pharma MRSN Mersana Therapeutics XNCR Xencor ARQL ArQule CAL Caleres NBTX

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Peter Lawson (BARCLAYS)